Siemens, Medtronic jump through antitrust regulatory hoops
This article was originally published in Clinica
US antitrust authorities has given the go-ahead to Siemens' proposed $7bn acquisition of Dade Behring, the German multinational's third and largest IVD transaction. Siemens began a tender offer for all issued and outstanding Dade stock, at $77 per share, on August 8 and has extended this offer until midnight September 26. The acquisition still requires EU antitrust approval - Siemens said it is in discussion with the European Commission and believes it can close the transaction during calendar 2007.